CRISPR-Cas9 genome editing exploits the CRISPR-Cas ... pegRNA scaffold incorporation is a common by-product of prime editing, compromising its precision and safety. Here, the authors show that ...

Deanna earned their PhD in cellular biology from McGill University in 2020 and has a professional background in medical writing. They are an associate science editor at The Scientist. View Full ...

The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell ...

But by combining a revolutionary new technology called CRISPR-Cas9 with a natural system known ... could count on steady supplies of genetically engineered insulin, made in the lab by placing ...

Intellia Therapeutics is a clinical-stage biotech company developing CRISPR-Cas9 gene-editing products designed for ... cell therapy's ability to deliver insulin independence with a one-time ...

When the CRISPR Cas9 protein is added to a cell along with a piece of guide RNA, the Cas9 protein hooks up with the guide RNA and then moves along the strands of DNA until it finds and binds to a ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.